Compare iShares Core High Dividend ETF (HDV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Tango Therapeutics Inc. — how do they compare? iShares Core High Dividend ETF trades at $29.71 (market cap $15.11B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: iShares Core High Dividend ETF is far larger — about 4× Tango Therapeutics Inc.'s market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 118 Days and Tango Therapeutics Inc. for 0 Days on average.
| HDV | TNGX | |
|---|---|---|
Market Cap | $15.11B | $3.75B |
Volume | 2,559,662 | 9,619,106 |
52-Week High | $29.93 | $32.90 |
52-Week Low | $23.64 | $7.50 |
Typical Hold Time | 118 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $29.15, up 0.28% with a bullish technical signal from moving averages. The ETF recently underwent a significant sector rebalance, reducing healthcare exposure while increasing energy, staples, and utilities. Technical indicators show strong momentum with RSI at 66.71 suggesting neutral conditions, while ADX readings indicate a strong trend. Recent dividend distributions of $0.10 and $0.06 demonstrate the fund's income-focused strategy.
The ETF's concentrated sector allocation (62% in three sectors) presents both opportunity and risk. While the 3% yield attracts income investors, the reduced diversification may increase vulnerability to sector-specific headwinds. Technical strength supports near-term upside, but investors should weigh the trade-off between current income and long-term growth potential given the sector concentration.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
